Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT019
MIFTS: 58

Hepatic Encephalopathy

Categories: Rare diseases, Neuronal diseases, Liver diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hepatic Encephalopathy

About this section

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 76 53 37 55 15 73
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 53
Hepatoencephalopathy 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:13413
ICD10 33 K72
ICD9CM 35 572.2
MeSH 44 D006501
NCIt 50 C79596
KEGG 37 H01506
UMLS 73 C0019151
Sources

Summaries for Hepatic Encephalopathy

About this section
NIH Rare Diseases : 53 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to alcoholic liver cirrhosis and hepatic coma. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Circadian entrainment and Immune response IL-23 signaling pathway. The drugs Simvastatin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

Wikipedia : 76 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may... more...

Sources

Related Diseases for Hepatic Encephalopathy

About this section

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 32.7 ALB F2 SLC17A5
2 hepatic coma 32.0 ALB F2 GPT TSPO
3 liver cirrhosis 31.7 ALB F2 GPT SLC17A5
4 hepatitis 31.0 F2 GPT SLC17A5 TNF
5 alcoholic hepatitis 30.5 ALB F2 GPT IL6 SLC17A5 TNF
6 acute liver failure 30.2 ALB F2 GC GPT SLC17A5 TSPO
7 peritonitis 30.1 ALB F2 IL6 TNF
8 meningitis 30.1 ALB IL6 TNF
9 portal hypertension 29.6 ALB F2 GPT TNF
10 brain edema 29.5 ALB GLUL IL6 SLC1A2 SLC25A13
11 hepatitis b 28.7 ALB F2 GPT SLC17A5 TNF
12 viral hepatitis 28.5 ALB F2 GPT SLC17A5 TNF
13 liver disease 28.4 ALB F2 GPT SLC17A5 SLC25A13 TNF
14 psychotic disorder 28.1 MAOB NOS1 S100B
15 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.3
16 combined oxidative phosphorylation deficiency 1 11.8
17 encephalopathy 11.0
18 3-hydroxyacyl-coa dehydrogenase deficiency 10.9
19 antipyrine metabolism 10.9 ALB F2
20 non-a-e hepatitis 10.9 ALB F2
21 hepatic veno-occlusive disease 10.9
22 hepatorenal syndrome 10.9
23 carnitine palmitoyltransferase i deficiency , muscle 10.9
24 congenital extrahepatic portosystemic shunt 10.9
25 scorpion envenomation 10.8 IL6 TNF
26 leukomalacia 10.8 IL6 TNF
27 angioimmunoblastic lymphadenopathy with dysproteinemia 10.7 IL6 TNF
28 fournier gangrene 10.7 ALB F2
29 critical limb ischemia 10.7 IL6 TNF
30 sudden sensorineural hearing loss 10.7 F2 IL6
31 marburg hemorrhagic fever 10.7 F2 TNF
32 streptococcal toxic-shock syndrome 10.7 IL6 TNF
33 abdominal tuberculosis 10.6 ALB F2
34 hemorrhagic fever with renal syndrome 10.6 ALB IL6 TNF
35 keratoconjunctivitis sicca 10.6 ALB IL6 TNF
36 atypical depressive disorder 10.6 MAOA MAOB
37 null-cell leukemia 10.6 IL6 TNF
38 pyelonephritis 10.6 ALB IL6 TNF
39 appendicitis 10.6 ALB IL6 TNF
40 intermittent claudication 10.6 ALB F2 IL6
41 filariasis 10.6 ALB IL6 TNF
42 gastroenteritis 10.6 ALB IL6 TNF
43 primary bacterial infectious disease 10.6 ALB IL6 TNF
44 intestinal disease 10.6 ALB IL6 TNF
45 hypersensitivity reaction disease 10.5 ALB IL6 TNF
46 end stage renal failure 10.5 ALB IL6 TNF
47 chronic fatigue syndrome 10.5 IL6 MAOA TNF
48 respiratory system disease 10.5 ALB IL6 TNF
49 ischemic heart disease 10.5 F2 IL6 TNF
50 otitis media 10.5 ALB IL6 TNF

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy
Sources

Symptoms & Phenotypes for Hepatic Encephalopathy

About this section

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 GLUL SLC1A2 IL6 SLC25A13 MAOA TNF
2 homeostasis/metabolism MP:0005376 10.17 GLUL SLC1A2 IL6 SLC25A13 MAOA TNF
3 mortality/aging MP:0010768 9.9 SLC17A5 GLUL SLC1A2 IL6 SLC25A13 ALB
4 liver/biliary system MP:0005370 9.8 GLUL IL6 SLC25A13 TNF ALB NOS1
5 nervous system MP:0003631 9.65 GLUL SLC1A2 IL6 SLC25A13 MAOA MAOB
6 normal MP:0002873 9.23 GLUL SLC1A2 ALB NOS1 F2 S100B
Sources

Drugs & Therapeutics for Hepatic Encephalopathy

About this section

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 274)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
4
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
5
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
6
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
7
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
8
Carvedilol Approved, Investigational Phase 4,Not Applicable 72956-09-3 2585
9
Nadolol Approved Phase 4,Phase 3,Not Applicable 42200-33-9 39147
10
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
11
Magnesium oxide Approved Phase 4 1309-48-4 14792
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Midodrine Approved Phase 4,Not Applicable 133163-28-7, 42794-76-3 4195
14
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
15
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
16
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
17
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
18
Tolvaptan Approved Phase 4,Phase 3 150683-30-0 216237
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2 142217-69-4 153941
21
Insulin Aspart Approved Phase 4 116094-23-6 16132418
22
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
23
Tranexamic Acid Approved Phase 4 1197-18-8 5526
24
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 70-26-8, 3184-13-2 6262
25
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
26 rifamycin SV Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
29 Adjuvants, Anesthesia Phase 4,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Rifamycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adrenergic alpha-1 Receptor Antagonists Phase 4
33 Adrenergic alpha-Antagonists Phase 4
34 Adrenergic Antagonists Phase 4,Phase 3,Not Applicable
35 Adrenergic beta-Antagonists Phase 4,Phase 3,Not Applicable
36 GABA Agents Phase 4,Phase 1,Phase 2,Not Applicable
37 GABA Modulators Phase 4,Phase 1,Phase 2,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Narcotics Phase 4,Not Applicable
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Analgesics, Opioid Phase 4,Not Applicable
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
44 Anesthetics Phase 4,Phase 2,Not Applicable
45 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
46 N-Methylaspartate Phase 4,Phase 3,Phase 2,Not Applicable
47 Anesthetics, General Phase 4,Not Applicable
48 Anesthetics, Intravenous Phase 4,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Tranquilizing Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 278)
# Name Status NCT ID Phase Drugs
1 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
2 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
3 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
4 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
5 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
9 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
10 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
11 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
12 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
13 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
14 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4 Albumin
15 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
16 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
17 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
18 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
19 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
20 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
21 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
22 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
23 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
24 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
25 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
26 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
27 Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" Completed NCT01201720 Phase 4
28 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
29 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
30 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
31 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
32 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4 Entecavir
33 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
34 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
35 Ramelteon for Treatment of Insomnia in Cirrhosis Recruiting NCT03091738 Phase 4 Ramelteon Pill
36 Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis Recruiting NCT01943617 Phase 4 Entecavir;Thymosin-α
37 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
38 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4 Rifaximin
39 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Recruiting NCT02695732 Phase 4 Carvedilol
40 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Recruiting NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
41 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Not yet recruiting NCT03077217 Phase 4 Rifaximin
42 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4 Tenofovir disoproxil fumarate
43 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
44 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
45 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4
46 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
47 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
48 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose
49 Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
50 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Hepatic Encephalopathy

About this section
Sources

Anatomical Context for Hepatic Encephalopathy

About this section

MalaCards organs/tissues related to Hepatic Encephalopathy:

41
Liver, Brain, Testes, Bone, Endothelial, Small Intestine, Cortex
Sources

Publications for Hepatic Encephalopathy

About this section

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 817)
# Title Authors Year
1
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
2
Comparison of prognostic systems in cirrhotic patients with hepatic encephalopathy ( 29914250 )
2018
3
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. ( 29428113 )
2018
4
Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? ( 29394969 )
2018
5
Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. ( 29341039 )
2018
6
Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. ( 29892171 )
2018
7
Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABA<sub>A</sub>R-TrkB interaction in minimal hepatic encephalopathy. ( 29404643 )
2018
8
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
9
Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision. ( 29872892 )
2018
10
Aberrant Brain Bile Acid Signaling and Cholesterol Accumulation: A New Look at Mechanisms in Hepatic Encephalopathy. ( 29928680 )
2018
11
Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data. ( 29849776 )
2018
12
CT Scan Is Still a Valuable Tool to Assess Hepatic Encephalopathy Pathophysiology in Both Acute and Chronic Liver Diseases. ( 29912129 )
2018
13
Hepatic encephalopathy: causes and health-related burden. ( 29411993 )
2018
14
Neuroinflammation in acute hepatic encephalopathy rats: imaging and therapeutic effectiveness evaluation using <sup>11</sup>C-PK11195 and <sup>18</sup>F-DPA-714 micro-positron emission tomography. ( 29968208 )
2018
15
Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. ( 29892178 )
2018
16
Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. ( 29856063 )
2018
17
Multimodal MR imaging in hepatic encephalopathy: state of the art. ( 29374342 )
2018
18
Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. ( 29881992 )
2018
19
Prediction of Hepatic Encephalopathy: Why disregard well known risk factors? ( 29377250 )
2018
20
Stroop Test Validation to Screen for Minimal Hepatic Encephalopathy in Pediatric Extrahepatic Portal Venous Obstruction. ( 29373442 )
2018
21
Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( 29352675 )
2018
22
Hepatic encephalopathy and cirrhotic cardiomyopathy in intensive care unit. ( 29624025 )
2018
23
Improving Quality of Care for People with Hepatic Encephalopathy. ( 29411992 )
2018
24
Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. ( 29383024 )
2018
25
Re: Prediction of Hepatic Encephalopathy: why disregard well known risk factors? ( 29365345 )
2018
26
Conservative management of severe serotonin syndrome with coma, myoclonus, and crossed-extensor reflex complicated by hepatic encephalopathy. ( 29686575 )
2018
27
FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy. ( 29928671 )
2018
28
Aberrant topological organization of the functional brain network associated with prior overt hepatic encephalopathy in cirrhotic patients. ( 29846883 )
2018
29
Direct comparison of the thioacetamide and azoxymethane models of Type A hepatic encephalopathy in mice. ( 29895352 )
2018
30
Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials. ( 29932239 )
2018
31
Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. ( 29313245 )
2018
32
EDITORIAL that refers to article 'Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study'. ( 29430750 )
2018
33
Diagnosis and management of hepatic encephalopathy. ( 29411990 )
2018
34
Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. ( 29935863 )
2018
35
Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. ( 29899437 )
2018
36
Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. ( 29863286 )
2018
37
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. ( 29417604 )
2018
38
Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. ( 29844325 )
2018
39
Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. ( 29341965 )
2018
40
Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration. ( 29882396 )
2018
41
Learning and Memory Impairments in Patients with Minimal Hepatic Encephalopathy are Associated with Structural and Functional Connectivity Alterations in Hippocampus. ( 29941971 )
2018
42
Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. ( 28776344 )
2017
43
Effects on cognitive function of propofol medium and long chain lipid emulsion in patients with hepatic encephalopathy. ( 28884566 )
2017
44
Hepatic Encephalopathy. ( 28079343 )
2017
45
Fecal microbiota transplantation for treating recurrent hepatic encephalopathy: Ready for clinical application? ( 28936973 )
2017
46
Predictive models of minimal hepatic encephalopathy for cirrhotic patients based on large-scale brain intrinsic connectivity networks. ( 28912425 )
2017
47
Hepatic Encephalopathy. ( 28069286 )
2017
48
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. ( 28799305 )
2017
49
Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm? ( 28929776 )
2017
50
Hepatic Encephalopathy. ( 28079344 )
2017
Sources

Variations for Hepatic Encephalopathy

About this section
Sources

Expression for Hepatic Encephalopathy

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.
Sources

Pathways for Hepatic Encephalopathy

About this section

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Circadian entrainment 37
Show member pathways
 12.67 GLS GLUL MAOA MAOB NOS1 SLC1A2
2
Immune response IL-23 signaling pathway 22
Show member pathways
 12.38 F2 IL6 NOS1 TNF
3
Folate Metabolism 1
Show member pathways
 12.04 ALB F2 IL6 TNF
4
Ca, cAMP and Lipid Signaling 4
11.86 ALB S100B TSPO
5
Spinal Cord Injury 1
11.81 IL6 NOS1 TNF
6
Amyotrophic lateral sclerosis (ALS) 1 37
Show member pathways
 11.77 NOS1 SLC1A2 TNF
7
Interleukin-4 and 13 signaling 66
11.76 IL6 MAOA TNF
8
Amino Acid metabolism 1
11.59 GLS GLUL MAOA
9
Arginine and proline metabolism 37
Show member pathways
 11.3 MAOA MAOB NOS1
10
Monoamine Transport 1
Show member pathways
 11.07 MAOA NOS1 TNF
11
Amino acid synthesis and interconversion (transamination) 66
Show member pathways
 10.94 GLS GLUL GPT
12
Overview of nanoparticle effects 1
10.85 IL6 TNF
13
noradrenaline and adrenaline degradation 1
Show member pathways
 10.69 MAOA MAOB
14
Alanine, aspartate and glutamate metabolism 37
10.68 GLS GLUL GPT
15
Dopamine metabolism 1
10.64 MAOA MAOB
16
putrescine degradation III 1
Show member pathways
 10.59 MAOA MAOB
17
Neurotransmitter uptake and Metabolism In Glial Cells 66
Show member pathways
 10.34 GLUL SLC1A2
18
Arginine biosynthesis 37
Show member pathways
 10.34 GLS GLUL GPT NOS1
Sources

GO Terms for Hepatic Encephalopathy

About this section

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ALB F2 GC GPT IL6 S100B
2 mitochondrion GO:0005739 9.17 GLS GLUL MAOA MAOB NOS1 SLC25A13

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.71 IL6 S100B TNF TSPO
2 positive regulation of chemokine production GO:0032722 9.43 IL6 TNF
3 L-glutamate transmembrane transport GO:0015813 9.37 SLC1A2 SLC25A13
4 neurotransmitter catabolic process GO:0042135 9.32 MAOA MAOB
5 negative regulation of lipid storage GO:0010888 9.26 IL6 TNF
6 dopamine catabolic process GO:0042420 9.16 MAOA MAOB
7 response to glucocorticoid GO:0051384 9.13 IL6 S100B TNF
8 cellular amino acid biosynthetic process GO:0008652 8.8 GLS GLUL GPT

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC1A2 SLC25A13
2 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB
Sources

Sources for Hepatic Encephalopathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....